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Abstract
The influenza surface glycoprotein neuraminidase (NA) is essential for the efficient spread of the virus. Antiviral drugs such
as Tamiflu (oseltamivir) and Relenza (zanamivir) that inhibit NA enzyme activity have been shown to be effective in the
treatment of influenza infections. The recent ‘swine flu’ pandemic and world-wide emergence of Tamiflu-resistant seasonal
human influenza A(H1N1) H274Y have highlighted the need for the ongoing development of new anti-virals, efficient
production of vaccine proteins and novel diagnostic tools. Each of these goals could benefit from the production of large
quantities of highly pure and stable NA. This publication describes a generic expression system for NAs in a baculovirus
Expression Vector System (BEVS) that is capable of expressing milligram amounts of recombinant NA. To construct NAs with
increased stability, the natural influenza NA stalk was replaced by two different artificial tetramerization domains that drive
the formation of catalytically active NA homotetramers: GCN4-pLI from yeast or the Tetrabrachion tetramerization domain
from Staphylothermus marinus. Both recombinant NAs are secreted as FLAG-tagged proteins to allow for rapid and simple
purification. The Tetrabrachion-based NA showed good solubility, increased stability and biochemical properties closer to
the original viral NA than the GCN4-pLI based construct. The expressed quantities and high quality of the purified
recombinant NA suggest that this expression system is capable of producing recombinant NA for a broad range of
applications including high-throughput drug screening, protein crystallisation, or vaccine development.
Citation: Schmidt PM, Attwood RM, Mohr PG, Barrett SA, McKimm-Breschkin JL (2011) A Generic System for the Expression and Purification of Soluble and Stable
Influenza Neuraminidase. PLoS ONE 6(2): e16284. doi:10.1371/journal.pone.0016284
Editor: Fernando Rodrigues-Lima, University Paris Diderot-Paris 7, France
Received August 20, 2010; Accepted December 22, 2010; Published February 7, 2011
Copyright:  2011 Schmidt et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Funding was provided by the National Institutes of Health (NIH) grant 5R01AI62721 ’Mechanisms of influenza NA drug resistance’ (http://www.nih.gov/),
the National Health and Medical Research Council (NHMRC) grant 595625 ’Impact of resistance mutations on sensitivity of A (H1N1) swine flu neuraminidase (NA) to
current and novel NA-inhibitors’ (http://www.nhmrc.gov.au/), and GlaxoSmithKline (http://www.gsk.com/). The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: All authors are employees of the Commonwealth Scientific Industrial Research Organisation (CSIRO). JLM is receiving funding from GSK
and the NIH. JLM and PMS receive funding from the NHMRC. The contents of this work are solely the responsibility of the authors and do not necessarily represent
the official views of the NIH, NHMRC or GSK. The authors also confirm that the above mentioned competing interests do not alter the authors’ adherence toa l l
the PLoS ONE policies on sharing data and materials.
* E-mail: Peter.Schmidt@CSIRO.au
Introduction
Human seasonal influenza is responsible for a world-wide death
toll of an estimated 250,000–500,000 and 3–5 million cases of
severe illness routinely every year (WHO influenza fact sheet
2009), a fact easily forgotten in light of the media presence during
the rapid spread of the ‘swine flu’ virus (human A(H1N1)-2009),
the first influenza pandemic in more than 4 decades. In the wake
of this newly emerged reassortant virus, the potential problems
associated with rapidly producing sufficient doses of vaccine for
millions of people became evident and highlighted the ongoing
need to improve the production of immunogenic proteins.
One of the major influenza proteins that represents an important
component of killed split vaccines is the viral neuraminidase (NA).
In its active form NA is a membrane bound homotetrameric
glycoprotein and its sialidase activity is essential for the release of
new virus particles from infected cells[1]. Inhibition of NA activity
by ethyl (3R,4R,5S)-5-amino-4-acetamido-3-(pentan-3-yloxy)cyclo-
hex-1-ene-1-carboxylate (Tamiflu, oseltamivir) and (2R,3R,4S)- 4-
[(diaminomethylidene)amino]- 3-acetamido- 2-[(1R,2R)- 1,2,3-tri-
hydroxypropyl]- 3,4-dihydro- 2H-pyran- 6-carboxylic acid (Re-
lenza, zanamivir) has proven to be effective in the treatment of
influenza infections[1,2]. However, NA inhibitor-resistant virus
strains have recently emerged such as the A(H1N1) seasonal human
influenzastrainwithanH274Ymutation,whichconfersresistanceto
Tamiflu [3,4,5]. Therefore, understanding the mechanisms behind
antiviral resistance and the continual development of new antivirals
based on that insight is critically important. Protein crystallisation
has been a powerful approach to explain mechanisms of resistance,
however the production of large amounts of highly purified NA has
been problematic. Methods based on the amplification of influenza
virus in eggs[6,7] or cell culture systems rely on the viability of the
virus. Often mutations that confer resistance have been shown to
compromise virus viability resulting in extremely low levels of
purified NA being obtained[8,9]. In addition, proteases have been
commonly used to cleave the NA head from the membrane[6,7] or
detergents were applied to solubilise the enzyme out of the viral
membrane[10]. However, viral NAs can become intrinsically
unstable once they are cleaved from the membrane[11] and lose
activity within hours and therefore impede any subsequent analysis.
Recent alternatives have included the production of recombi-
nant NA in eukaryotic expression systems, for example
yeast[12,13] or insect cells[14,15,16]. Both systems have been
limited to date by the low yield of tetrameric, active NA[12,15] or
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membrane[16,17]. Although the use of cleavage site-specific
proteases (e.g. Thrombin) has overcome the problem of non-
specific cleavage they still could render the stalk-less NA head
prone to dissociation into non-active NA monomers or dimers.
The generic expression system outlined in the present publication
aims to overcome these obstacles by a combination of the melittin
signalling peptide (MSP) secretion signal[18], FLAG tag[19] and
the use of two artificial tetramerization domains from yeast
(GCN4-pLI, [20,21]) and the deep sea archae bacterium
Staphylothermus marinus (Tetrabrachion, [22]). The latter has been
shown to be stable at temperatures up to 130uC making it a
potentially good choice to stabilize a tetrameric active form of
secreted soluble NA[23]. We demonstrated that a recombinant
human N1 NA with an artificial Tetrabrachion stalk is stable and
shares more similarities with the original viral NA when compared
to the same protein with the yeast stalk GCN4-pLI.
Results
Construction of a generic expression system
In order to allow the expression of a broad range of NAs and to
identify conserved regions in the NA stalk domain, a multi-
sequence alignment of 43 NA sequences ranging from N1 to N9
(1918–2007) was performed (for a complete list of included
influenza strains see table S1). The result shows that although the
NA stalk is highly variable, a stretch of 4 residues (70–73 based on
N2 numbering) shows a higher degree of similarity (Fig. 1A). As it
has previously been shown that the NA stalk can have an impact on
NA catalytic activity [24,25,26,27],theseamino acids were included
in the construction of the expression system, especially as they
represent a predicted glycosylation site for various NAs. Sequences
encoding the tetramerizing domains from yeast (transcription factor
GCN4-pLI[21]) and Staphylothermus marinus (Tetrabrachion[22,23])
were combined with an up- or downstream FLAG-tag resulting in 4
Figure 1. Construction of the expression system. (A) To identify potentially important domains in the NA stalk, 43 NA sequences covering N1 to
N9 from 1918 to 2007 were included in the alignment (for details see Table S1). The inset shows the level of homology of the sequences for the NA
domains, namely the cytoplasmatic domain, the transmembrane domain (TM), the stalk- and the head-domain. The alignment shows that although
the majority of the stalk is not conserved a small stretch shows a higher degree of similarity. Amino acids 70–73 (based on N2 numbering) of this
stretch were included in the expression system (the beginning of the region indicated by red line). (B) The sequences encoding for the 4 artificial NA
constructs where cloned into pFastBac upstream from an MSP sequence using EcoRI and XbaI.
doi:10.1371/journal.pone.0016284.g001
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were amplified, fused to the NA head of Hokkaido N1 by PCR and
cloned into the Vector pFastBac downstream of a MSP secretion
signal[28].
Characterizing and optimizing the expression system
Sf21 cells were infected with all 4 constructs at a Multiplicity of
infection (MOI) of 1, 2, 3, and 4 and the respective NA activity in
the media was measured after 0 h, 24 h, 48 h, and 72 h. As shown
in figure 2, increasing the MOI above 1 did not result in increased
expression levels of NA. All constructs but construct 1 showed
strong NA activity in the media (Fig. 2) as well as strong signals in
the corresponding anti-FLAG western blots (Figure S1). As
construct 1 showed only negligible NA activity and low expression
levels it was not further pursued.
Thermal stability studies showed that constructs 2–4 were stable
at RT in SF900 II media for 3 days compared to control samples
stored on ice (Fig. 3A). Incubation of the samples for this time at
37uC resulted in a strong decrease in the observed NA activity.
The membrane-bound full length recombinant Hokkaido NA that
was used as control was stable under these conditions. To
demonstrate that the secreted NAs were truly soluble we showed
that the NA activity in the supernatant remained unchanged after
1 h of centrifugation at 40,000 g (Fig. 3B).
Low pH is a convenient way to elute bound proteins from
affinity columns and although the Tetrabrachion stalk has been
reported to be stable at extreme pH[22], NA is known to lose its
activity under these conditions[29,30]. To determine if the
artificial NAs were stable under low pH conditions, constructs
2–4 in SF 900II media were diluted in glycine buffer pH 2.8 for
different times before measuring their activity. The data in
figure 3C shows clearly that even a short-term incubation of 1
minute at low pH conditions reduced the NA activity by more
than 90% (Fig. 3C) with construct 3 being more vulnerable than
constructs 2 and 4.
In order to further optimize the expression system, Sf21
(Spodoptera frugiperda) cells were compared to Hi5 (Trichopulsia ni)
insect cells as the latter cell line has been reported to give higher
yields especially of secreted proteins. Both cell lines were infected
with baculoviruses encoding for constructs 3 or 4 at a MOI of 1
and the secreted NA activity was monitored in the media for 72 h.
As shown in figure 4A both cell lines secreted similar amounts of
active NA independent of the construct. The viability of Hi5 cells
seemed to drop faster (Fig. 4B) after infection compared to Sf21
cells, however, this did not affect the total amount of secreted NA
activity. Western blots of the expression kinetics of both constructs
showed strong expression of the respective NA constructs (Fig. 4C,
D) in both cell lines whereas the signal seemed to drop slightly for
the Hi5 expression after 72 h. As Sf21 cells are lower maintenance
than Hi5 cells all further NAs were expressed in Sf21 cells.
Large scale expression of construct 2 and 4
Based on the results obtained from the optimization, large-scale
Sf21 cultures were infected with the respective baculovirus stock to
produce larger amounts of the different NA constructs. The NA
expression and purification process was exemplified by the
purification of construct 4. The accumulation of secreted NA
over the time was monitored via its activity to ensure optimal
yields (data not shown). In parallel, media samples were taken to
track expression of construct 4 by PAGE and western blot (Fig. 5A,
B). Although low in sensitivity, UV imaging of the gel (Fig. 5A)
subsequently used for anti-FLAG western blot (Fig. 5B) showed
that construct 4 was detectable. Anti-FLAG affinity chromatog-
raphy, as an initial purification step, was already sufficient to
purify the enzyme to virtual homogeneity as supported by the
Coomassie stained gel (Fig. 5C) and the respective western blot
(Fig. 5D). In addition, whereas the Coomassie stained gel showed
the presence of a variety of proteins in the insect cell media
(Fig. 5C; lane Flowthrough) the western blot indicated that all
FLAG-reactive protein was pulled out of the media in a single run
(Fig. 5D; lane FT) reflecting a total amount of 7 mg construct 4
(1.8 mg per litre culture). In order to further purify construct 4, the
enzyme was concentrated and subjected to gel filtration chroma-
tography. The chromatogram showed some high molecular weight
impurities (Fig. 5E, peak 1) and a further peak (Fig. 5E, peak 3)
that reflected the FLAG peptide used to elute construct 4 from the
affinity column. The major peak (Fig. 5E, peak 2) contained the
entire enzymatic activity of the sample (data not shown), and was
concentrated down for subsequent characterization. The purity of
construct 4 NA was estimated to be ,99% based on the
Coomassie stained gel and the corresponding anti-FLAG western
blot (Fig. 5F). Construct 2 was also purified to homogeneity
following the same protocol (data not shown), however, the total
yield of construct 2 was usually only around 20–30% (0.5mg per
litre) when compared to construct 4 indicating that the use of the
Tetrabrachion stalk resulted in higher yields. The molecular
weights of construct 2 and 4 were estimated by MALDI-ToF to be
54.6 kDa and 58.5 kDa, respectively. The N-terminal sequence of
Figure 2. Optimizing MOI. To optimize the MOI, Sf21 cells were infected with all 4 constructs at a MOI of 1 (white bars), 2 (light gray bars), 3 (dark
gray bars) and 4 (black bars). NA activity in the media was measured at 0 h, 24 h, 48 h and 72 h. Increasing the MOI did not have any significant
impact on the amount of secreted NA activity. This experiment was performed once in duplicate.
doi:10.1371/journal.pone.0016284.g002
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Construct 3, although active in the media, was purified as two
peaks in the gel filtration chromatography of which only the large
molecular weight peak showed NA activity (data not shown). This
result indicated that construct 3 was unstable during purification
resulting in a mixture of active tetrameric NA and a non-active
fraction of lower molecular weight potentially monomeric or
dimeric NA.
Biochemical characterization of the purified artificial NAs
To determine the specific activity of the purified constructs 2
and 4 the enzymes were subjected to a 4-Methylumbelliferyl N-
acetyl-a-D-Neuraminic acid (MUNANA) activity assay in the
presence of excess substrate immediately after purification.
Figure 6 shows the accumulation of fluorescent product over time
for constructs 2 and 4. Based on the linear slope of both curves
(FUs/sec), a 4-Methylumbelliferone (MU) standard, and the
concentration of the enzyme in the assay, a specific activity of
387626.7 and 377612.7 pmol/sec/mg was calculated for
construct 2 and construct 4 respectively (Table 1). To test whether
the purified enzymes show comparable characteristics to the
original viral NA, the Km value for MUNANA as well as the IC50
values for the NA-inhibitors were determined. To calculate the
IC50 values the Hokkaido virus and both recombinant enzymes
were pre-incubated with increasing concentrations of NA
inhibitors, oseltamivir, zanamivir and (1S,2S,3S,4R)-3-[(1S)-1-
acetamido-2-ethyl-butyl]-4- (diaminomethylideneamino)-2-hydroxy-
cyclopentane- 1-carboxylic acid (peramivir). The maximal observed
catalytic rate for each reaction (FU/min) was measured and
plotted against the respective inhibitor concentration. The IC50
values for oseltamivir, zanamivir, and peramivir were 3.72 nM,
1.37 nM, and 0.37 nM for the original Hokkaido virus (Fig. 7A).
For construct 2 the IC50s were 12.5 nM, 11.6 nM, and 1.79 nM
(Fig. 7B), whereas the values calculated for construct 4 were
slightly lower, 8.67 nM, 4.93 nM, and 0.82 nM (Fig. 7C; Table 1).
To investigate whether the exchange of the stalk had influenced
the affinity towards the NA substrate, Km values for the Hokkaido
virus and both recombinant enzymes were determined by
incubating the NAs with increasing concentrations of MUNANA
in the absence or presence of NA-inhibitors oseltamivir,
zanamivir, and peramivir (Fig. 8, 9, 10). The Km value for the
Hokkaido virus NA was 24.1 mM whereas the values for the
recombinant enzymes were 54.4 mM and 34.7 mM for construct 2
and construct 4, respectively (Table 1). The Ki values for
oseltamivir, zanamivir, and peramivir derived from the obtained
Km of the three NAs and the concentration of the respective NA
inhibitor are summarized in Table 1. Construct 4 showed similar
Ki values for oseltamivir, zanamivir, and peramivir (3.70 nM,
3.10 nM, 0.51 nM) compared to the Hokkaido virus (3.78 nM,
1.28 nM, 0.5 nM) whereas construct 2 had slightly elevated
values (Table 1).
Discussion
Despite seasonal influenza being responsible for a world-wide
death toll of more than 250,000 per year, the availability of anti-
viral therapies and vaccines have reduced the public concern
about this common viral disease. However, this dramatically
changed with the rapid spread of ‘swine flu’ and the world-wide
emergence of the Tamiflu-resistant seasonal A(H1N1) H274Y
human influenza. In the light of these incidents it is evident that
understanding the emergence of resistance, the need to quickly
develop sufficient doses of vaccine, and the development of new
antiviral drugs are vital for the effective control of influenza. These
Figure 3. Characterization of secreted NA in media. (A) The
different NA-containing media were incubated for 3 days on ice, RT, or
37uC. The secreted soluble construct 2–4 were stable at RT but not at
37uC whereas the membrane bound full length Hokkaido N1 was stable
at all temperatures. (B) Centrifugation of construct 2–4 containing
media for 1 h at 40,000 g did not affect the amount of detected NA
activity. (C) Incubation of construct 2–4 containing media at pH 2.8
abolished most of the NA activity of construct 2–4 within 1 min. This
experiment was performed once in duplicate.
doi:10.1371/journal.pone.0016284.g003
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amounts of stable and soluble NA making a robust, reliable, and
universal expression system for this enzyme highly desirable. This
publication describes a generic system that expresses highly soluble
NA with biochemical and immunological properties close to the
original virus NA. The production of purified NA may allow its
use for various applications including high throughput screening
for small molecule inhibitors, generation of anti-NA antibodies,
binding assays, serotyping, protein crystallisation, or even
vaccination.
The influenza stalk domain, although its sequence is poorly
conserved, can be a major contributor to the stability of the
homotetrameric structure of NA. Others have shown that secreted
NA with a slightly truncated transmembrane domain resulted in
the formation of monomeric, dimeric and tetrameric NA [12,15].
These results suggest that the replacement of the NA stalk by more
stable and rigid domains that are known to form parallel
homotetrameric structures could promote greater NA stability.
This approach was first formulated by Fiers et al. for influenza
NA[20] and its feasibility to promote homotetramerization has
been shown for proteins such as the influenza M2 [31] or human
p53[32]. These publications made use of the yeast transcription
factor GCN4 as a heterologous domain to promote tetrameriza-
tion. Natural GCN4 forms parallel homodimers, however slight
modifications of the residues in the dimer interface result in the
stable formation of homotrimers or tetramers making this protein
a very versatile tool[21]. As GCN4 has been shown to successfully
promote tetramerization it was used as an artificial stalk for
construct 1 and 2 described in this work. In general, domains that
form parallel homotetramers are rare and a literature search
revealed only artificial domains based on GCN4[33,34] as well as
two further natural domains, namely the tetramerization domain
from the vasodilator-stimulated phosphoprotein (VASP)[35,36,37]
and the protein Tetrabrachion from the deep sea archae bacteria
Staphylothermus marinus[22,23]. Based on its structural properties to
form a straight parallel homotetramer[23,36] and its stability even
at high temperature[22,23] the tetramerization domain from
Tetrabrachion was used as the basis for constructs 3 and 4. To
facilitate purification of the recombinant NA a FLAG tag was
introduced N- (construct 2 and 4) or C-terminal from the
tetramerization domain (construct 1 and 3). FLAG was chosen
as it consists of only 8 residues and can increase the solubility of
fused proteins [19,38]. To enable purification from the media, the
NA sequence was cloned downstream from a melittin signal
peptide (MSP) sequence allowing recombinant proteins to be
secreted from insect cells[18,28].
Previously it was shown that even small modifications of the NA
stalk are able to modulate the activity of the enzyme[27]. Contrary
observations have been reported with respect to the introduction
of a FLAG tag into the NA stalk domain. Some reports showed
that the introduction of the affinity tag does not affect NA
activity[39,40] whereas Castrucci and co-workers reported a
negative impact of this stalk modification on the catalytic rate[24].
In agreement with the latter report we found that the insertion of
the FLAG tag in close proximity to the NA head had a strong
destabilizing effect on the enzyme’s tetrameric structure. This
negative impact was reflected by the very low NA activity of
construct 1 and the inability to purify construct 3 in a homogenous
tetrameric state. This dissociation into catalytically inactive
monomeric and dimeric NA due to the instability of the NA
Figure 4. Comparing Sf21 and Hi5 insect cells. To optimize the expression system Sf21 cells were compared to Hi5 cells. (A) There was no
significant difference in the amount of secreted NA activity observed for construct 3 or 4 in both cell lines. (B) Cell viability seemed to drop faster for
Hi5 compared to Sf21 cells without affecting the amount of secreted NA activity. (C, D) Anti-FLAG western blot of construct 3- or 4-containing media
showed a strong signal for both cell lines. Activity and viability data are duplicates of three independent infections. For the respective western blots
the supernatants of all three infections were pooled.
doi:10.1371/journal.pone.0016284.g004
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recombinant NA[12,15]. In striking contrast, construct 4 was
stable, suggesting that the presence of FLAG in close proximity to
the NA head disturbs the assembly of functional tetramers. A
potential reason for the destabilizing effect might be the
accumulation of 20 (4 FLAG tags) negatively charged aspartic
acids in the tetrameric state resulting in electrostatic repulsion.
The fact that construct 3 can be expressed as a functional protein
Figure 5. Large scale expression and purification exemplified by construct 4. To obtain sufficient amounts of NA, larger (5l) Sf21 cultures
were infected and the respective NA was purified from the media. (A) UV protein imaging and (B) western blot of the 40,000 g media samples
following the NA expression over 96 h. (C, D) Peptide eluted fractions from the anti-FLAG affinity matrix stained by Coomassie (C) or anti-FLAG
western blot (D). (E) Gel filtration chromatogram of the FLAG-purified construct 4 recorded at 280 nm wavelength. (F) Purified construct 4 stained by
Coomassie (left panel) or by anti-FLAG western blot (right panel).
doi:10.1371/journal.pone.0016284.g005
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stalk domain is able to confer a higher level of stability compared
to the GCN4-pLI domain used for constructs 1 and 2. This view is
supported by the fact that under natural conditions Tetrabrachion
is stable at 130uC[22,23]. This data suggests that in agreement
with work published by Xu and co-workers[37] the affinity tag
should be placed at the N-terminus of the recombinant NA to
avoid interference with the formation of functional homotetra-
mers. Moreover, the presence of 4 single N-terminal FLAG tags in
the NA-tetramer seemed to result in a very high avidity as the
entire FLAG reactive NA was pulled out of the media in a single
run making this purification approach highly efficient and
powerful.
The data from the optimization of the expression system shows
that the secreted NAs (constructs 2 and 4) are highly active and
soluble as the activity in the media was not decreased by
ultracentrifugation, in contrast to membrane bound NA expressed
in insects cells[16]. In addition, both enzymes retained their
activity in insect cell media for weeks, even at room temperature
(data not shown) underlining their improved stability. Neverthe-
less, the recombinant NAs were still vulnerable to low pH with
construct 3 being less stable than construct 2 and 4. As the
Tetrabrachion stalk used for construct 3 and 4 has been shown to
be stable at a pH range from 1–11.5[22] the susceptibility of all
artificial NA constructs to low pH is presumably due to the pH
sensitivity of the NA head in agreement with published
work[29,30].
The optimization of expression conditions indicated that neither
increasing the MOI beyond 1 nor expressing the recombinant
NAs in Hi5 cells which require more maintenance than Sf21 insect
cells increased the yields of soluble NA, in contrast to published
results by others[37]. These results show that the NA expression
system described here can produce high yields of NA. Milligram
amounts of construct 4 NA per litre of insect cell culture were
obtained from large scale expressions without obvious destabiliza-
tion of the NA tetramer (based on size exclusion chromatography)
or breakdown products (based on SDS-PAGE and western blot) as
has previously been the case[12,15,16]. Compared to construct 4,
construct 2 resulted in lower yields favouring the Tetrabrachion-
based system for the expression or larger quantities of NA. The
predicted molecular weights of secreted constructs 2 and 4 are
49.1 kDa and 51.2 kDa, respectively, however, when analysed by
MALDI-ToF a slightly higher molecular weight of 54.6 kDa and
Table 1. Biochemical properties of different NAs.
Hokkaido virus Construct 2 Construct 4
N-terminal sequencing - AEFDYKDDD… AEFDYKDDD…
specific activity (pmol/sec/mg) - 387626.7 377612.7
turnover number (molecules/sec/head) - 79.465.5 77.262.6
Km value for MUNANA (mM) 24.161.1 54.164.4 34.761.9
IC50 oseltamivir (nM) 3.7260.45 12.561.9 8.6761.33
zanamivir (nM) 1.3760.20 11.661.8 4.9360.73
peramivir (nM) 0.3760.03 1.7960.21 0.8260.1
Ki oseltamivir (nM) 3.7860.20 5.3760.96 3.7060.05
zanamivir (nM) 1.2860.07 3.8560.75 3.1960.22
peramivir (nM) 0.5060.03 1.4260.04 0.5160.13
The table shows the determined biochemical properties of the original Hokkaido virus NA and the artificial NAs derived from this virus. In addition, the IC50 and Ki values
for the common NA-inhibitors oseltamivir, zanamivir, and peramivir are shown for all 3 NAs.
doi:10.1371/journal.pone.0016284.t001
Figure 6. Maximal catalytic activity. To determine the specific
activity of construct 2 (A) and 4 (B) a MUNANA activity assay was
performed in excess substrate and at enzyme dilutions that allowed the
enzyme reaction to remain linear over time. Data represents mean 6
SEM (upper and lower line; mean is omitted for clarity) of 4
independent experiments performed in duplicate.
doi:10.1371/journal.pone.0016284.g006
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5.5 kDa for construct 2 and 7.3 kDa for construct 4 as well as
the broad shape of the band in the SDS-PAGE suggest that
both enzymes are glycosylated, a common phenomena for
NA[12,13,15]. Glycosylation of recombinant proteins expressed
in insect cells are of a simpler high-mannose type compared to
proteins expressed in mammalian cells[41] with an average
molecular weight of approximately 1.3 kDa[41,42]. The observed
increase in molecular weight of 5.5 kDa and 7.3 kDa suggests 4
and at least 5 glycosylation sites for construct 2 and construct 4
respectively. Although the exact numbers of glycosylation sites for
both enzymes have not been determined yet, these results are in
good agreement with the predicted number of glycosylation sites
being 4 for construct 2 and 5–6 for construct 4.
As a first step to biochemically characterize construct 2 and 4,
the specific activity of both recombinant NAs was measured in a
standard MUNANA activity assay. To determine the maximal
catalytic rate with highest accuracy these assay were performed in
the presence of excess substrate (1 mM) and at an enzyme
dilution that allowed linear reaction conditions for an adequate
time interval. Whereas former publications[15,16,43] needed to
add high pH buffer to the enzymatic reaction in order to increase
the MU fluorescence (thereby stopping the reaction), modern
fluorescence plate readers allow the continuous recording of the
catalytic conversion of MUNANA[5]. The specific activity based
on the first derivative of the recorded enzymatic reaction (FU/
sec) and a MU standard was determined to be 387 and
377 pmol/sec/mg that converts to a turnover number of 79 and
77 substrate molecules per second per NA tetramer. These values
are slightly lower than values reported by others for example
870 pmol/sec/mg for N9 G70C NA[43]. However, it should be
taken into account that these calculations rely on many variables
e.g. the estimation of the protein concentration or the
preparation of purified NA for example via proteolytic cleavage
that might already affect the determined activities. Nevertheless,
these values suggest that the nature of the artificial stalk did not
seem to influence the specific activity under maximum substrate
conditions. This result was not anticipated as the yeast GCN4
domain forms a slightly left-handed coiled coil structure whereas
the Tetrabrachion domain forms a nearly parallel bundle[36].
Although the maximal catalytic activity was not affected, there
were differences between the original virus NA and constructs 2
and 4 with respect to the Km values for MUNANA. The native
Hokkaido virus NA had a Km value of 24.1 mM in good
agreement with other influenza A virus strains[4]. In contrast the
estimated Km value for construct 2 was more than twice as high
(54.1 mM) whereas construct 4 showed a Km value that was closer
to the original NA (34.7 mM). As all three enzymes share the
same NA head these results might indicate that the slightly
different twisting of the stalks[36] affected the positioning of the 4
monomers towards each other and as a consequence the observed
affinity towards the NA substrate. It would be interesting to
compare these results with an NA construct based on the VASP
tetramerization domain that forms a right handed coiled-coil
structure[36]. Unfortunately there has been no data published
describing the biochemical properties of these recombinant
enzymes[37,44].
The decreased affinity for the NA substrate MUNANA was also
reflected in the observed IC50 values for the NA inhibitors
oseltamivir, zanamivir, and peramivir. Whereas the Hokkaido
virus NA showed IC50 values in the range observed for various
influenza A viruses[45] both recombinant enzymes, especially
construct 2, showed increased IC50 values for all 3 drugs. These
findings were supported by the Ki values derived from the enzyme
Figure 7. Determination of IC50s. To validate whether constructs 2
and 4 showed similar IC50 values for NA inhibitors, the enzymes (B, C) as
well as the original Hokkaido virus (A) were incubated with increasing
concentrations of oseltamivir, zanamivir, and peramivir. Data represents
mean 6 SEM of 4 independent experiments performed in duplicate.
doi:10.1371/journal.pone.0016284.g007
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constant takes into account the decreased affinity for the substrate
MUNANA in the absence of drugs making the Ki values a more
reliable comparison between the original Hokkaido virus NA and
the two recombinant enzymes. The Ki values for all three
inhibitors for construct 4 were close to the ones obtained for the
original virus NA, whereas construct 2 showed generally higher
values. These results, in combination with the observed higher Km
value for construct 2, indicate that the replacement of the natural
NA stalk by the yeast GCN4 stalk did affect the biochemical
properties of the NA homotetramer, presumable by the twisted
left-handed coiled-coil structure that has been reported for this
domain[36].
In summary, this publication describes the construction and
characterization of a generic baculovirus expression system for
influenza NA that allow the production and straight forward
purification of milligram amounts of NA from cell culture media.
The results presented here indicate that the use of the
Tetrabrachion tetramerization domain from the deep sea archae
bacterium Staphylothermus marinus confers higher stability to the
expressed and secreted NA than the yeast GCN4-pLI stalk. In
addition, the Tetrabrachion-based recombinant NA is closer to
the original viral NA with respect to its biochemical character-
istics than the GCN4-based NA, making this system the preferred
choice wherever stable and active NA is needed. The purified NA
is a good candidate for biochemical applications ranging from
high throughput screening for small molecule NA-inhibitors,
production of monoclonal anti-NA antibodies, diagnostic appli-
cations, crystallisation studies or the generation of protein
vaccines.
Materials and Methods
Materials
MUNANA was obtained from Carbosynth (Compton, Berk-
shire, UK). Neuraminidase inhibitors zanamivir, oseltamivir, and
peramivir were synthesized at GlaxoSmithKline (Stevenage, UK).
All other chemicals including MU were of analytical grade and
purchased from Sigma-Aldrich (Castle Hill, Australia). FLAG
peptide was ordered from Peptide2.0 (Chantilly, VA, USA).
Monoclonal anti-FLAG M2 antibody was produced and purified
at CSIRO, (Parkville, Australia). NAs were purified in Tris buffer
[25 mM] pH 6.5 containing 10 mM Ca
2+, and 0.02% azide
(TBA). For activity assays NAs were diluted in TBA/BSA with a
final concentration of BSA of 0.25 mg/ml (IC50 determinations) or
1 mg/ml (specific activity), respectively.
Cells, virus, and media
Sf21 (Spodoptera frugiperda) and Hi5 (Trichopulsia ni) insect cells,
cultured in SF 900 II (Invitrogen, Carlsbad, CA) or Express Five
(Invitrogen) serum free medium, were used for baculovirus
amplification and protein production. Influenza virus strain A/
Figure 8. Determination of Km and Ki values for the Hokkaido virus. To determine the Km value for MUNANA as well as the Ki values for the
three NA-inhibitors for the original Hokkaido virus, virus particles were incubated with increasing concentrations of substrate in the absence (A) or
presence of oseltamivir (B), zanamivir (C), or peramivir (D). Data represents mean 6 SEM of 4 independent experiments performed in duplicate.
doi:10.1371/journal.pone.0016284.g008
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was amplified in Madin-Darby Canine Kidney (MDCK) cells
propagated in maintenance medium (1:1 mix of MEM media
pH 6.8/L15 media pH 7.6, sodium bicarbonate [0.028%], HEPES
pH 6.8 [20 mM], Fungizone [1 mg/ml], PenStrep/Glutamine).
Construction of recombinant NA
Sequence construction and alignment was performed using
Vector NTI (Invitrogen, Carlsbad, CA). cDNA was obtained by
RT-PCR from influenza virus strain Hokkaido. The sequence
encoding the NA head and a residual fragment of the original
NA stalk was amplified using the primers Hokkaido-Stalk/
H o k k a i d o - H e a da ss h o w ni nT a b l e2 .T h es e q u e n c e sf o rt h e
artificial stalks including FLAG-tag were synthesized by
GeneART (Regensburg, Germany). The artificial stalks were
fused to the NA head via PCR using the relevant construct
primer shown in Table 2. The PCR products were cloned into
the transfer vector pFastBac downstream of the coding sequence
for the MSP responsible for the secretion of the expressed
protein[18]. As a control for some experiments, a baculovirus
encoding the full length Hokkaido NA including the natural
stalk as well as the transmembrane domain was generated. In
the absence of a secretion signal the respective NA was
expressed as membrane bound enzyme. Each DNA sequence
was verified by sequencing (Micromon, Victoria, Australia).
Bacmids and baculovirus particles were constructed using the
Bac-to-Bac system (Invitrogen, Carlsbad, CA) according to the
manufacturer’s protocols.
Expression and purification of recombinant NAs
Recombinant NA-constructs were expressed in Sf21 insect cells
(Invitrogen, Carlsbad, CA) cultured in SF 900II serum free medium
(Invitrogen, Carlsbad, CA). Cells were infected at a density of
2610
6/ml with an MOIof 1. Secreted NAactivity in the media and
cell viability were assessed every day. 4 days post-infection cells, cell
debris, and baculovirus were spun down (40,000 g, 1 h, 4uC) and
the cleared supernatant was filtered through 1.2 mm and 0.22 mm
filters. Azide and the protease inhibitor E-64[46] were added to a
final concentration of 0.02% and 1 mM, respectively. The cleared
supernatant was run overnight through a 50 ml anti-FLAG affinity
column (Mini-Leak Low; Kem-En-Tec A/S, Copenhagen, Den-
mark) at 4uC and bound protein was eluted by TBA buffer
containing 0.25 mg/ml FLAG peptide (DYKDDDDK). The NA
containing fractions, identified by their activity, were pooled, and
concentrated down to 1 ml by using 10 kDa cutoff spin concentra-
tor (Millipore Amicon Ultra-4). Subsequently, the concentrated NA
sample was further purified via gel filtration on a Superose12
column (GE Healthcare, Rydalmere, NSW, Australia) using a
BioLogic DuoFlow System equipped with a QuadTec UV-Vis
detector (Bio-Rad, Gladesville, NSW, Australia). The NA-contain-
ing fractions were pooled and concentrated down for further
analysis.
SDS-PAGE and Western blotting
SDS-PAGE was performed using NuPAGE (Invitrogen,
Carlsbad, CA) or iGels (NuSep, Frenchs Forest, NSW, Australia)
precast gels according to the manufacturer’s protocols. Protein
Figure 9. Determination of Km and Ki values for construct 2. To determine the Km value for MUNANA as well as the Ki values for the three NA-
inhibitors for construct 2, purified enzyme was incubated with increasing concentrations of substrate in the absence (A) or presence of oseltamivir (B),
zanamivir (C), or peramivir (D). Data represents mean 6 SEM of 4 independent experiments performed in duplicate.
doi:10.1371/journal.pone.0016284.g009
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stain[47], or UV by using the protein stain NUView, which is
already incorporated in iGels. Western blots were performed using
the iBlot system (Invitrogen, Carlsbad, CA) according to the
manufacturer’s protocol. Transferred FLAG-tagged proteins were
visualized as described elsewhere[48], briefly, the nitrocellulose
membrane was blocked using 1% Casein/PBS and subsequently
incubated with anti-FLAG mAb in 1% Casein/PBS (1/1000).
After washing, membranes were incubated with secondary
antibody (anti-mouse-HRP; ImmunoBioScience, Mukilteo, WA)
in 1% Casein/PBS (1/10000). Immunoreactive proteins were
detected using TMB (3,39,5,59-Tetramethylbenzidine) as de-
scribed[48] except that dextran sulphate [1%] was added directly
to the TMB substrate solution as it was found to improve colour
development.
N-terminal sequencing
The N-terminal sequences of the purified proteins were
determined by automated Edman degradation in a Hewlett-
Packard G1000A sequencer as described elsewhere[49].
Neuraminidase activity assay
The activity of expressed NAs was measured based on published
protocols using the fluorescent NA substrate MUNANA[50,51]
with the modification that fluorescence was monitored continu-
ously. Briefly, purified enzyme, cleared cell culture supernatant, or
influenza virus particles were diluted in TBA. The enzyme
reaction was initiated by adding 2-fold concentrated acetate buffer
Figure 10. Determination of Km and Ki values for construct 4. To determine the Km value for MUNANA as well as the Ki values for the three NA-
inhibitors for construct 4, purified enzyme was incubated with increasing concentrations of substrate in the absence (A) or presence of oseltamivir (B),
zanamivir (C), or peramivir (D). Data represents mean 6 SEM of 4 independent experiments performed in duplicate.
doi:10.1371/journal.pone.0016284.g010
Table 2. Primers used to amplify and fuse artificial stalk and
NA head.
Name direction Sequence
Construct 1 forward 5-GCATCGGAATTCCTGAAGCAGATCGAGG-3
Construct 2/4 forward 5- GCATCGGAATTCGACTACAAGGACGACG-3
Construct 3 forward 5- GCATCGGAATTCGGTTCCATCATCAACG-3
Hokkaido-Stalk forward 5-CAACACCAATGTTATTGCTGGAAAGGAC-3
Hokkaido-Stalk reverse 5-CACCAATGTTATTGCTGGAAAGGACAAA
ACTTC-3
Hokkaido-Head reverse 5-GCTCTAGATTACTACTTGTCAATGGTGAAT
GGCAAC-3
All primers are shown in 59 to 39 direction. The underlined nucleotides
represent the restriction sites (EcoRI, XbaI) used for subsequent cloning into
pFastBac-MSP.
doi:10.1371/journal.pone.0016284.t002
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2+ [10 mM] and MUNANA
[200 mM]. Enzyme activity was measured by continuously
monitoring the increasing fluorescence of the reaction product
MU (excitation: 355 nm, emission 460 nm) in black 96 well plates
(PerkinElmer, California, USA) for 60 min at 37uC. Fluorescence
was recorded using a Fluostar OPTIMA plate reader (BMG
Labtech, Mornington, Australia) and data was subsequently
analysed using MARS data analysis software (BMG).
pH sensitivity. To determine whether low pH has an impact
on the activity of the recombinant NAs 50 ml of constructs 2–4 in
SF 900II media were diluted
1/20 in glycine buffer pH 2.8
[200 mM] followed by subsequent neutralisation with Tris buffer
pH 8.7 [1 M] after 1 min, 15 min, and 30 min. The remaining
NA activity was determined by standard MUNANA assay as
described above.
IC50 determination. In order to determine the IC50 values
for zanamivir, oseltamivir and peramivir for the original virus
(Hokkaido) as well as for the recombinant soluble NA constructs,
the concentration of NA was titrated to ensure linearity of the
enzyme reaction over time. The respective NA dilution in TBA/
BSA was pre-incubated with increasing concentrations of NA
inhibitors for 30 min at 37uC. The enzyme reaction was started by
the addition of MUNANA-containing substrate buffer as
described above. The maximum rate of enzyme activity (FU/
min) was calculated for each reaction and graphed against the
respective inhibitor concentration. IC50 values were defined as the
inhibitor concentration that caused a 50% reduction of the
maximum catalytic rate of the no-drug-control.
Specific activity. Specific activities of purified NAs were
determined in the presence of excess MUNANA [1 mM final
concentration] to avoid substrate depletion. The maximum
activity of each enzyme (FU/min) was calculated from three
different enzyme concentrations. A MU standard was included to
allow the conversion of FU into molarities.
Kinetic parameters. In order to determine the Km values for
the original virus NA and the recombinant soluble NAs, the
enzymes were incubated with increasing concentrations of
MUNANA (3 mM–600 mM) in the absence and presence of the
NA inhibitors zanamivir, peramivir, or oseltamivir for 30 min at
37uC. The enzyme reaction was started by adding substrate-buffer
and the reaction was monitored for 60 min at 37uC as described
above. Data was analysed using MARS data analysis software
(BMG). The highest observed enzyme rate (FU/min) was plotted
against the substrate concentration. The Km values for MUNANA
as well as the Ki values for the NA inhibitors zanamivir,
oseltamivir, and peramivir were determined by PRISM 5
(GraphPad Software, La Jolla, USA) using the non-linear
regression for mixed-mode inhibition.
Supporting Information
Figure S1 Expression kinetic of construct 1-4. Anti-FLAG
western blots of Sf21 supernatants without infection (72 h control)
or infected with construct 1-4 (MOI 1). Samples of infected cells
were taken at the indicated time points.
(TIF)
Table S1 Names of influenza strains included in the
initial alignment. The table lists the names and the NA/HA
composition of the 43 influenza strains from 1918-2007 which NA
sequences (N1-N9) were included in the initial multisequence
alignment shown in figure 1.
(DOC)
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